TCTMD’s Top 10 Most Popular Stories for September 2020
Half of TCTMD’s top stories this month are from the virtual ESC Congress, but topping the list was the Daily COVID-19 Dispatch.
Half of TCTMD’s top stories for the month of September stemmed from the European Society of Cardiology’s virtual 2020 Congress, with a study of colchicine in stable CAD leading the pack. Topping the list, however, was TCTMD’s Daily COVID-19 Dispatch. Now entering its seventh month, the Dispatch is a daily compilation of top research and policy news related to SARS-CoV-2. Rounding out the list are a comparison of TAVR devices, a consensus statement on CT angiography in chronic CAD, a pilot study that dropped aspirin following PCI for stable disease, and a heartfelt farewell to James T. Willerson, MD.
We’re curating a list of COVID-19 research and other useful content, and updating it daily.
Colleagues and friends remember a warm, funny person with a legendary work ethic who cared deeply for his patients.
On top of last year’s COLCOT results, the new findings add fuel to the inflammatory hypothesis, researchers say.
More-potent antiplatelet therapy should be used with caution in patients older than 80 years, authors suggest.
No valve is better than the others for most patients, but experts say certain variables can sway their choice.
The SGLT2 inhibitor is the second such agent to show a significant benefit in the treatment of HF, even in those without diabetes.
Their recommendations range from increasing payment and access to providing more education to referring physicians.
Quick MI rule-out, noninvasive imaging, simpler anticoagulation, SCAD, and MINOCA—all get their due in this year’s update.
The proof-of-concept study takes “dropping aspirin” to a new level, never introducing the antiplatelet post-PCI in the first place.
With PARAGON-HF, this is the second trial that failed to show an overwhelming benefit in this hard-to-treat population.
* * *